Now that AstraZeneca PLC’s diabetes drug Farxiga has got a game-changing approval for heart failure in the US, the company believes indication-based pricing makes sense for the SGLT2 inhibitor given its potential for keeping thousands of patients out of hospital.
The US Food and Drug Administration approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalization in adults...




